AR080737A1 - Uso de un inhibidor de la proteinquinasa c ( pkc) - Google Patents
Uso de un inhibidor de la proteinquinasa c ( pkc)Info
- Publication number
- AR080737A1 AR080737A1 ARP110101038A ARP110101038A AR080737A1 AR 080737 A1 AR080737 A1 AR 080737A1 AR P110101038 A ARP110101038 A AR P110101038A AR P110101038 A ARP110101038 A AR P110101038A AR 080737 A1 AR080737 A1 AR 080737A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- dione
- protein kinase
- pharmaceutical agent
- cell lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901310P | 2010-03-30 | 2010-03-30 | |
| US201061425525P | 2010-12-21 | 2010-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080737A1 true AR080737A1 (es) | 2012-05-02 |
Family
ID=44710357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101038A AR080737A1 (es) | 2010-03-30 | 2011-03-30 | Uso de un inhibidor de la proteinquinasa c ( pkc) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8748428B2 (https=) |
| EP (1) | EP2552428A1 (https=) |
| JP (1) | JP2013523678A (https=) |
| KR (2) | KR101461767B1 (https=) |
| CN (1) | CN102821759A (https=) |
| AR (1) | AR080737A1 (https=) |
| AU (1) | AU2011234644B2 (https=) |
| BR (1) | BR112012024585A2 (https=) |
| CA (1) | CA2795456A1 (https=) |
| MX (1) | MX2012011341A (https=) |
| RU (1) | RU2012146083A (https=) |
| WO (1) | WO2011120911A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| KR101723786B1 (ko) | 2014-03-28 | 2017-04-06 | 가톨릭대학교 산학협력단 | Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물 |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| AU2017295858A1 (en) | 2016-07-14 | 2019-01-24 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| WO2020092924A1 (en) * | 2018-11-02 | 2020-05-07 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489608A (en) | 1989-12-21 | 1996-02-06 | Goedecke Aktiengesellschaft | Indolocarbazole derivatives and the use thereof |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| PT657458E (pt) | 1993-12-07 | 2002-02-28 | Lilly Co Eli | Inibidores de proteina cinase c |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
| SI0776895T1 (en) | 1995-11-20 | 1999-04-30 | Eli Lilly And Company | Protein kinase C inhibitor |
| EP2070921A1 (en) * | 2000-11-07 | 2009-06-17 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| US6645970B2 (en) * | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2005041953A1 (en) | 2003-10-24 | 2005-05-12 | Eli Lilly And Company | Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases |
| EP1799699A1 (en) | 2004-10-13 | 2007-06-27 | Wyeth | Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| CA2599320A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| JP2008531538A (ja) | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008000463A (es) | 2005-07-11 | 2008-03-11 | Novartis Ag | Derivados de indolil-maleimida. |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| JP5161102B2 (ja) | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| MX2009005950A (es) | 2006-12-07 | 2009-10-12 | Genentech Inc | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
-
2011
- 2011-03-28 KR KR1020127025582A patent/KR101461767B1/ko not_active Expired - Fee Related
- 2011-03-28 AU AU2011234644A patent/AU2011234644B2/en not_active Ceased
- 2011-03-28 EP EP11713996A patent/EP2552428A1/en not_active Withdrawn
- 2011-03-28 CA CA2795456A patent/CA2795456A1/en not_active Abandoned
- 2011-03-28 US US13/073,652 patent/US8748428B2/en not_active Expired - Fee Related
- 2011-03-28 MX MX2012011341A patent/MX2012011341A/es not_active Application Discontinuation
- 2011-03-28 KR KR1020147022716A patent/KR20140107685A/ko not_active Withdrawn
- 2011-03-28 WO PCT/EP2011/054709 patent/WO2011120911A1/en not_active Ceased
- 2011-03-28 JP JP2013501783A patent/JP2013523678A/ja active Pending
- 2011-03-28 CN CN2011800155365A patent/CN102821759A/zh active Pending
- 2011-03-28 RU RU2012146083/15A patent/RU2012146083A/ru not_active Application Discontinuation
- 2011-03-28 BR BR112012024585A patent/BR112012024585A2/pt not_active IP Right Cessation
- 2011-03-30 AR ARP110101038A patent/AR080737A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012011341A (es) | 2012-11-12 |
| EP2552428A1 (en) | 2013-02-06 |
| WO2011120911A1 (en) | 2011-10-06 |
| JP2013523678A (ja) | 2013-06-17 |
| AU2011234644B2 (en) | 2014-07-17 |
| AU2011234644A1 (en) | 2012-10-11 |
| US20110245256A1 (en) | 2011-10-06 |
| KR101461767B1 (ko) | 2014-11-13 |
| KR20140107685A (ko) | 2014-09-04 |
| KR20120133389A (ko) | 2012-12-10 |
| CN102821759A (zh) | 2012-12-12 |
| BR112012024585A2 (pt) | 2016-05-31 |
| RU2012146083A (ru) | 2014-05-10 |
| US8748428B2 (en) | 2014-06-10 |
| CA2795456A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kocak et al. | Targeting autophagy in disease: established and new strategies | |
| Raudenska et al. | Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers | |
| RU2014124184A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 | |
| AR080737A1 (es) | Uso de un inhibidor de la proteinquinasa c ( pkc) | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR088730A1 (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| KR20180013851A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| UA119537C2 (uk) | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ | |
| DOP2010000012A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| PE20141197A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| NZ753024A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| US20200147058A1 (en) | Kras inhibitor for use in treating cancer | |
| WO2021026349A1 (en) | Combination therapy for treatment of cancer | |
| CA2718472A1 (en) | Use of phosphatases to treat neuroblastomas and medulloblastomas | |
| PH12013500581A1 (en) | Pharmaceutical combinations | |
| JP2013523678A5 (https=) | ||
| Yan et al. | Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors | |
| RU2012148706A (ru) | Комбинация органичемких соединений | |
| US10213436B2 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| Yang et al. | Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line | |
| Martins et al. | Autophagy Modulation for Organelle-Targeting | |
| EP3592868A1 (en) | Methods of treatment of cancer with reduced ubb expression | |
| PH12013502048B1 (en) | Therapeutic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |